126 related articles for article (PubMed ID: 2717622)
1. Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis.
Pandolfi A; Florita M; Altomare G; Pigatto P; Donati MB; Poggi A
Proc Soc Exp Biol Med; 1989 May; 191(1):1-4. PubMed ID: 2717622
[TBL] [Abstract][Full Text] [Related]
2. [Growth factors in the pathogenesis of progressive systemic sclerosis].
Altomare GF; Polenghi MM; Pigatto PD; Florita S; Finzi AF
G Ital Dermatol Venereol; 1989 May; 124(5):187-92. PubMed ID: 2620917
[TBL] [Abstract][Full Text] [Related]
3. Dipyridamole decreases platelet-derived growth factor levels in human serum.
Takehara K; Grotendorst GR; Silver R; LeRoy EC
Arteriosclerosis; 1987; 7(2):152-8. PubMed ID: 3579723
[TBL] [Abstract][Full Text] [Related]
4. Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma.
Bryckaert M; Fontenay M; Lioté F; Bellucci S; Carriou R; Tobelem G
Ann Rheum Dis; 1994 Nov; 53(11):776-9. PubMed ID: 7826142
[TBL] [Abstract][Full Text] [Related]
5. Raised serum hyaluronate levels in scleroderma: an effect of growth factor induced activation of connective tissue cells?
Engström-Laurent A; Feltelius N; Hällgren R; Wasteson A
Ann Rheum Dis; 1985 Sep; 44(9):614-20. PubMed ID: 3876080
[TBL] [Abstract][Full Text] [Related]
6. Immunoassay of platelet-derived growth factor in the plasma of patients with scleroderma.
Dunbar PR; Harrison A; Corkill MM; Neale TJ
Br J Rheumatol; 1993 Nov; 32(11):966-71. PubMed ID: 8220935
[TBL] [Abstract][Full Text] [Related]
7. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis.
Solanilla A; Villeneuve J; Auguste P; Hugues M; Alioum A; Lepreux S; Ducroix JP; Duhaut P; Conri C; Viallard JF; Nurden AT; Constans J; Ripoche J
Rheumatology (Oxford); 2009 Sep; 48(9):1036-44. PubMed ID: 19549789
[TBL] [Abstract][Full Text] [Related]
8. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera.
Loizos N; Lariccia L; Weiner J; Griffith H; Boin F; Hummers L; Wigley F; Kussie P
Arthritis Rheum; 2009 Apr; 60(4):1145-51. PubMed ID: 19333919
[TBL] [Abstract][Full Text] [Related]
9. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
10. Induction by growth factors from platelets of the focus-forming transformed phenotype in carcinogen-treated C3H/10T1/2 fibroblasts.
Mordan LJ
Carcinogenesis; 1988 Jul; 9(7):1129-34. PubMed ID: 3383332
[TBL] [Abstract][Full Text] [Related]
11. Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor.
Takemura H; Suzuki H; Fujisawa H; Yuhara T; Akama T; Yamane K; Kashiwagi H
J Rheumatol; 1998 Aug; 25(8):1534-9. PubMed ID: 9712097
[TBL] [Abstract][Full Text] [Related]
12. Purification of human platelet-derived growth factor.
Raines EW; Ross R
Methods Enzymol; 1985; 109():749-73. PubMed ID: 3990574
[No Abstract] [Full Text] [Related]
13. In vitro platelet aggregability studies: lack of evidence for platelet hyperactivity in systemic sclerosis.
Price JE; Klimiuk PS; Jayson MI
Ann Rheum Dis; 1991 Aug; 50(8):567-71. PubMed ID: 1888199
[TBL] [Abstract][Full Text] [Related]
14. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis.
Lima J; Fonollosa V; Fernández-Cortijo J; Ordi J; Cuenca R; Khamashta MA; Vilardell M; Simeón CP; Picó M
J Rheumatol; 1991 Dec; 18(12):1833-6. PubMed ID: 1839040
[TBL] [Abstract][Full Text] [Related]
15. Increased platelet-derived mitogenic activity in plasma of young patients with coronary atherosclerosis.
Nilsson J; Svensson J; Hamsten A; de Faire U
Atherosclerosis; 1986 Sep; 61(3):237-43. PubMed ID: 2429675
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders.
Katoh O; Kimura A; Kuramoto A
Am J Hematol; 1988 Apr; 27(4):276-80. PubMed ID: 3354562
[TBL] [Abstract][Full Text] [Related]
17. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis.
Classen JF; Henrohn D; Rorsman F; Lennartsson J; Lauwerys BR; Wikström G; Rorsman C; Lenglez S; Franck-Larsson K; Tomasi JP; Kämpe O; Vanthuyne M; Houssiau FA; Demoulin JB
Arthritis Rheum; 2009 Apr; 60(4):1137-44. PubMed ID: 19333949
[TBL] [Abstract][Full Text] [Related]
18. Increased platelet sensitivity to collagen-induced aggregation in whole blood patients with systemic sclerosis.
Goodfield MJ; Orchard MA; Rowell NR
Clin Exp Rheumatol; 1988; 6(3):285-8. PubMed ID: 3180549
[TBL] [Abstract][Full Text] [Related]
19. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation.
Macko RF; Gelber AC; Young BA; Lowitt MH; White B; Wigley FM; Goldblum SE
J Rheumatol; 2002 Dec; 29(12):2565-70. PubMed ID: 12465153
[TBL] [Abstract][Full Text] [Related]
20. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor.
Ohba T; McDonald JK; Silver RM; Strange C; LeRoy EC; Ludwicka A
Am J Respir Cell Mol Biol; 1994 Apr; 10(4):405-12. PubMed ID: 7510986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
